Sharenet Sites 
Sharenet Sites
Trading statement for the year ended 30 September 2026
LIFE HEALTHCARE GROUP HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
(Registration number: 2003/002733/06)
ISIN: ZAE000145892
JSE and A2X share code: LHC
("Life Healthcare" or "the Group" or "the Company")
LIFE HEALTHCARE FUNDING LIMITED
(Incorporated in the Republic of South Africa with limited liability)
(Registration number 2016/273566/06)
LEI: 3789SJPQJZF8ZYXTZ394
Bond company code: LHFI
(“Life Healthcare Funding”)
TRADING STATEMENT FOR THE YEAR ENDED 30 SEPTEMBER 2026
As previously communicated, the earnings for the year ended 30 September 2026 (current year) have been significantly impacted by
the disposal of Life Molecular Imaging (LMI) in FY2025 (prior year), distorting the comparability between the two financial periods.
The disposal of LMI in the prior year resulted in a R2.4 billion net gain. Due to the required accounting treatment of the disposal, it
impacted earnings per share (EPS) and headline earnings per share (HEPS) to various degrees. The fair value adjustment of R2.9
billion included in the net gain impacted EPS and HEPS from continuing and discontinued operations and, due to the pre-existing
nature of the Piramal liability (which remains with the Group), it also impacted both EPS and HEPS from continuing operations. The
fair value adjustment was, however, excluded from normalised earnings per share (NEPS).
The table below summarises the expected earnings for the current year. NEPS, which excludes non-trading related items, better reflects
the performance of our southern African underlying business.
Earnings per share FY2026 FY2025 Pro forma Pro forma % change Pro forma
(cents) (expected) (reported) adjustments FY2025 FY2026 % change
FY2025 (reported) (expected) vs FY2026
(reported) (note 1) FY2025 (expected) vs
(reported) FY2025
(pro forma)
From continuing
operations
NEPS +106.3 to +111.3 100.3 - 100.3 6% to 11% 6% to 11%
EPS +94.1 to +98.8 -106.9 201.0 94.1 >100% 0% to 5%
HEPS +100.7 to 106.0 -93.9 201.0 107.1 >100% -1% to - 6%
From continuing and
discontinued
operations
EPS +84.2 to +97.3 263.0 - 263.0 -63% to -68% -63% to -68%
HEPS +96.0 to +100.5 -112.1 201.0 88.9 >100% +8% to +13%
Notes
1. Pro forma information
To provide a more realistic assessment of the Group’s performance for the prior year, pro forma financial information has been
included in this announcement. The FY2025 pro forma numbers are derived by adding back the fair value adjustment relating to
the Piramal liability to the FY2025 audited results.
The directors are responsible for the pro forma financial information, which has been prepared in compliance with paragraphs 11.8
to 11.18 of the Listings Requirements of the JSE Limited and the SAICA Guide on Pro forma Financial Information, revised and
issued in September 2014 (applicable criteria). The pro forma information does not constitute financial information fairly presented
in accordance with IFRS Accounting Standards.
The pro forma information has been prepared for illustrative purposes only and, due to its nature, may not fairly present the Group’s
financial position, changes in equity, results of operations or cash flows. The underlying information used in the preparation of the
pro forma financial information has been prepared using the accounting policies of the Group in place for FY2026.
The Group’s FY2026 results are still in the process of being finalised. Life Healthcare expects to release its results for the year ended
30 September 2026 on or about 26 November 2026.
The estimated financial information on which this trading statement is based has not been reviewed, or reported on, by Life Healthcare’s
external auditors.
For further information, please email: Investor.Relations@lifehealthcare.co.za
Dunkeld
12 November 2026
Equity Sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited)
Debt Sponsor: Questco Corporate Advisory
Date: 12/11/2026 02:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
